Mirati (MRTX) Reiterated at Outperform by Cowen, Dec PDUFA is a Surprise but Earlier Approval Possible, Doesn't Change Valuation
Tweet Send to a Friend
Cowen analyst Tyler Van Buren reiterated an Outperform rating on Mirati Therapeutics (NASDAQ: MRTX), announcement that the FDA has set ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
